logo
Share SHARE
FONT-SIZE Plus   Neg

Silence Therapeutics Promotes Tony Sedgwick To CEO - Quick Facts

Silence Therapeutics plc (SLN.L) announced the promotion of Tony Sedgwick to the role of chief executive from chief business officer, effective immediately, and the departure of Thomas Christély who has resigned as a director of the company for personal reasons but would ensure a smooth transition.

Anthony David Sedgwick, with an extensive experience from European life science companies including over 15 years at Roche, joined Silence in September 2011 to lead a new business development team. Prior to joining
Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS. Earlier, Tony was also CEO of two acquired companies namely Daniolabs Ltd. and Cambridge Biotechnology Ltd.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations.
comments powered by Disqus
Follow RTT